Neurocognitive correlates of the use of combined Antiretroviral Therapy among HIV-infected adults attending care and treatment center at Muhimbili National Hospital, Dar es Salaam, Tanzania: An analytical cross-sectional study
DOI:
https://doi.org/10.4314/tmj.v27i1.201Keywords:
HIV-associated neurocognitive deficits (HAND), Antiretroviral, Central nervous system penetration, Muhimbili National Hospital, Dar es Salaam, TanzaniaAbstract
Background:The discovery of the highly active antiretroviral therapy has improved the life span of people living with HIV/AIDS (PLWHA) to almost that of the general population. This, however, has been coupled with increased incidences of HIV-associated dementia, especially mild cognitive impairment. Combined antiretroviral therapy (cART) has been observed to improve neurocognitive functions but the ART regimen that is best suited for improvement of neurocognitive functions is still largely unknown. This study was aimed at determining how neurocognitive deficits in patients on cART were related to ART regimen.
Methods:This was a cross-sectional analytical study. A sample of 351 adult patients attending care and treatment center (CTC) at Muhimbili National Hospital (MNH) in Dar es salaam, Tanzania were screened for HIV-associated neurocognitive deficits (HAND) against the ART regimens the patients were using. The study that was conducted from July to August 2012 and employed a standardized tool known as International HIV Dementia Scale (IHDS). Analysis was done using SPSS version 18. Frequency distribution, Chi-square, Fisher’s exact test and multivariate regression analysis were calculated to determine the levels of risk which was set at 5% significance level (p < 0.05).
Results:Two hundred and forty of the 351 (68.4%) patients screened positive for neurocognitive deficits. Under descriptive statistics, factors such as age, years of formal education, central nervous system penetration effectiveness (CPE) score and the use of efavirenz containing regimens showed statistically significant association with HAND at p=0.03, p=0.038, p<0.001 and p=0.039, respectively, while on multivariate analysis only ART combination with CPE based on 2010 scoring system showed significant association system (p=0.02, AOR=0.449 and C.I=0.27-0.748) with HAND.
Conclusion:These findings support the hypothesis that specific ART factors such as CPE may be protective against neurocognitive deficits. The study also highlights the need to choose appropriate ART regimen with special consideration to their potential neurotoxic side effect. Individual assessment for best therapeutic response is crucial for the patients’ cognitive wellbeing.
References
Gulick RM. Antiretroviral Treatment 2010: Progress and Controversies. J Acquir Immune Defic Syndr 1999. 2010 Dec 1;55(Suppl 1):S43–8.
Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011 Feb;17(1):3–16.
Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010 Dec 7;75(23):2087–96.
Elbirt D, Mahlab-Guri K, Bezalel-Rosenberg S, Gill H, Attali M, Asher I. HIV-associated neurocognitive disorders (HAND). Isr Med Assoc J IMAJ. 2015 Jan;17(1):54–9.
Seggane Musisi EK, editor. Psychiatric Problems of HIV/AIDS and their management in Africa. Kampala-Uganda: Fountain Publishers; 2009.
Lawler K, Mosepele M, Ratcliffe S, Seloilwe E, Steele K, Nthobatsang R, et al. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study. J Int AIDS Soc. 2010;13:15.
Liner KJ, Ro MJ, Robertson KR. HIV, antiretroviral therapies, and the brain. Curr HIV/AIDS Rep. 2010 May;7(2):85–91.
Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med Publ Int AIDS Soc USA. 2010 May;18(2):45–55.
Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, et al. Effects of Central Nervous System Antiretroviral Penetration on Cognitive Functioning in the ALLRT Cohort. AIDS Lond Engl. 2011 Jan 28;25(3):357–65.
Tan IL, McArthur JC. HIV-associated neurological disorders: a guide to pharmacotherapy. CNS Drugs. 2012 Feb 1;26(2):123–34.
Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 Jan;65(1):65–70.
Hong S, Banks WA. Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. Brain Behav Immun. 2015 Mar;45:1–12.
Spudich S, González-Scarano F. HIV-1-Related Central Nervous System Disease: Current Issues in Pathogenesis, Diagnosis, and Treatment. Cold Spring Harb Perspect Med [Internet]. 2012 Jun [cited 2015 Aug 18];2(6). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3367536/
Eisfeld C, Reichelt D, Evers S, Husstedt I. CSF penetration by antiretroviral drugs. CNS Drugs. 2013 Jan;27(1):31–55.
Decloedt EH, Rosenkranz B, Maartens G, Joska J. Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations. Clin Pharmacokinet. 2015 Jun;54(6):581–98.
Wright E. Neurocognitive impairment and neuroCART. Curr Opin HIV AIDS. 2011 Jul;6(4):303–8.
Akay C, Cooper M, Odeleye A, Jensen BK, White MG, Vassoler F, et al. Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system. J Neurovirol. 2014 Feb;20(1):39–53.
Home - MUHIMBILI NATIONAL HOSPITAL [Internet]. [cited 2015 Sep 23]. Available from: http://www.mnh.or.tz/
Dar es Salaam. In: Wikipedia, the free encyclopedia [Internet]. 2015 [cited 2015 Sep 26]. Available from: https://en.wikipedia.org/w/index.php?title=Dar_es_Salaam&oldid=680085549
Antiretroviral CNS Penetration-Effectiveness (CPE) 2010 ranking predicts CSF viral suppression only in patients with undetectable HIV-1 RNA in plasma [Internet]. [cited 2015 Aug 23]. Available from: http://www.natap.org/2011/CROI/croi_139.htm
HU X, ZHOU Y, LONG J, FENG Q, WANG R, SU L, et al. Diagnostic accuracy of the International HIV Dementia Scale and HIV Dementia Scale: A meta-analysis. Exp Ther Med. 2012 Oct;4(4):665–8.
Hestad KA, Menon JA, Silalukey-Ngoma M, Franklin DR, Imasiku ML, Kalima K, et al. Sex differences in neuropsychological performance as an effect of human immunodeficiency virus infection: a pilot study in Zambia, Africa. J Nerv Ment Dis. 2012 Apr;200(4):336–42.
Morlat P, Parneix P, Douard D, Lacoste D, Dupon M, Chêne G, et al. Women and HIV infection: a cohort study of 483 HIV-infected women in Bordeaux, France, 1985-1991. The Groupe d’Epidémiologie Clinique du SIDA en Aquitaine. AIDS Lond Engl. 1992 Oct;6(10):1187–93.
Marder K, Liu X, Stern Y, Malouf R, Dooneief G, Bell K, et al. Risk of human immunodeficiency virus type 1-related neurologic disease in a cohort of intravenous drug users. Arch Neurol. 1995 Dec;52(12):1174–82.
Bouwman FH, Skolasky RL, Hes D, Selnes OA, Glass JD, Nance-Sproson TE, et al. Variable progression of HIV-associated dementia. Neurology. 1998 Jun;50(6):1814–20.
Ritchie SJ, Bates TC, Deary IJ. Is Education Associated With Improvements in General Cognitive Ability, or in Specific Skills? Dev Psychol. 2015 May;51(5):573–82.
Gottesman RF, Rawlings AM, Sharrett AR, Albert M, Alonso A, Bandeen-Roche K, et al. Impact of Differential Attrition on the Association of Education With Cognitive Change Over 20 Years of Follow-up. Am J Epidemiol. 2014 Apr 15;179(8):956–66.
Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, et al. Antiretroviral therapy CNS penetration and HIV-1–associated CNS disease. Neurology. 2011 Feb 22;76(8):693–700.
Obiabo YO, Ogunrin OA, Ogun AS. Effects of highly active antiretroviral therapy on cognitive functions in severely immune-compromised HIV-seropositive patients. J Neurol Sci. 2012 Feb 15;313(1-2):115–22.
Funes HA, Apostolova N, Alegre F, Blas-Garcia A, Alvarez A, Marti-Cabrera M, et al. Neuronal bioenergetics and acute mitochondrial dysfunction: a clue to understanding the central nervous system side effects of efavirenz. J Infect Dis. 2014 Nov 1;210(9):1385–95.
Vigliano P, Boffi P, Bonassi E, Gandione M, Marotta C, Rainò E, et al. Neurophysiologic exploration: a reliable tool in HIV-1 encephalopathy diagnosis in children. Panminerva Med. 2000 Dec;42(4):267–72.
Funes HA, Blas-Garcia A, Esplugues JV, Apostolova N. Efavirenz alters mitochondrial respiratory function in cultured neuron and glial cell lines. J Antimicrob Chemother. 2015 Aug;70(8):2249–54.
Apostolova N, Funes HA, Blas-Garcia A, Galindo MJ, Alvarez A, Esplugues JV. Efavirenz and the CNS: what we already know and questions that need to be answered. J Antimicrob Chemother. 2015 Jul 22;
Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, et al. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology. 2014 Jul 8;83(2):134–41.